DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Journal article

Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was 14,397 euro for the cascade genetic compared with the cascade clinical approach. Genetic ...

Expand abstract

Authors: Wordsworth, S; Leal, J; Blair, E; Legood, R; Thomson, K

• Publication status: Published
• Journal: European heart journal
• Volume: 31
• Issue: 8
• Pages: 926-935
• Publication date: 2010-04-01
• DOI: 10.1093/eurheartj/ehq067
• EISSN: 1522-9645
• ISSN: 0195-668X
• Language: English
• Keywords: Humans; Decision Trees; Cardiomyopathy, Hypertrophic, Familial; Genetic Testing; Risk Assessment; Child; Forecasting; Sensitivity and Specificity; Middle Aged; Adult; Models, Economic; Death, Sudden, Cardiac; Pedigree; Cost-Benefit Analysis; Adolescent; Young Adult; Aged